Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.60 |
| ▸ | MAOA | P21397 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5974513 | 0.90 | MAOB (0.68) | MAOBMAOAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3933866 | 0.86 | MAOB (0.64) | MAOBMAOAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1436064 | 0.85 | KMT2A (0.76) | MAOBMAOAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL28858409 | 0.85 | KMT2A (0.71) | KMT2ARAB9A | |
| SCHEMBL4315663 | 0.85 | MAOB (0.62) | MAOBMAOAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL11874012 | 0.84 | KMT2A (0.56) | KMT2A | |
| SCHEMBL1606555 | 0.84 | MAPT (0.54) | KMT2ASMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL11737749 | 0.83 | MAOB (0.69) | MAOBMAOAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1436145 | 0.83 | THRB (0.65) | MAOBMAOAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1436453 | 0.83 | MAOB (0.60) | MAOBMAOAKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210748-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2017-07-27 | — | — | US | disclosed |
| US-9585886-B2 | ASK1 inhibiting pyrrolopyrimidine derivatives | CALCHAN LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2016-03-10 | — | — | US | disclosed |
| EP-2374794-B1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-9045485-B2 | ASK 1 inhibiting pyrrolopyrimidine derivatives | Convergence Pharmaceuticals Limited (GB) | 2015-06-02 | — | — | US | disclosed |
| US-20140038957-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited | 2014-02-06 | — | — | US | disclosed |
| EP-2374788-B1 | INDANYL COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2013-04-03 | — | — | EP | disclosed |
| US-8183272-B2 | Indanyl compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319359-A1 | INDANYL COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2374794-A1 | CYCLIC AMINE COMPOUNDS | Daiichi Sankyo Company, Limited (JP) | 2011-10-12 | — | — | EP | disclosed |
| EP-2374788-A1 | INDANYL COMPOUNDS | Daiichi Sankyo Company, Limited (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-7871998-B2 | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| EP-1699759-B1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-10-20 | — | — | EP | disclosed |
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20080064676-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| EP-1699759-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005061452-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210748-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | YES1, IRAK1, TBK1 | MAOB 3958/4885MAOA 4127/4885KMT2A 2342/4885 |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | YES1, IRAK1, TBK1 | MAOB 3958/4885MAOA 4127/4885KMT2A 2342/4885 |
| US-20140038957-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | YES1, IRAK1, TBK1 | MAOB 3958/4885MAOA 4127/4885KMT2A 2342/4885 |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | RYR2, CASR, RYR1 | MAOB 573/4885MAOA 589/4885KMT2A 2928/4885 |
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | CYP46A1, CYP51A1, DHCR7 | MAOB 622/4885MAOA 990/4885KMT2A 3616/4885 |
| US-20080064676-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | CYP46A1, CYP51A1, DHCR7 | MAOB 622/4885MAOA 990/4885KMT2A 3616/4885 |
| US-20110319359-A1 | INDANYL COMPOUNDS | RYR2, ORAI1, CASR | MAOB 3077/4885MAOA 3334/4885KMT2A 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.